Exosomal miRNA profiling in ER-positive metastatic breast cancer treated with CDK4/6 inhibitors

Plasma samples were collected at treatment initiation, and exosomes were isolated for unbiased microRNA expression profiling using microarray technology. Patients were clinically stratified according to endocrine sensitivity at baseline and progression status under CDK4/6 inhibition.

The resulting dataset was generated as an exploratory discovery cohort to identify candidate exosomal microRNAs associated with treatment outcome and resistance. These data provide a resource for investigating microRNA programs in the context of CDK4/6 inhibitor response.